XML 51 R43.htm IDEA: XBRL DOCUMENT v3.26.1
Restatement of Prior Period Financial Statements - Summary of Restated Consolidated Statements of Stockholders' Equity (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Dec. 31, 2024
Sep. 30, 2024
Dec. 31, 2024
Mar. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Balance at the beginning       $ 47,248 $ 47,248 $ 47,248 $ 47,248 $ 202
Exercise of Series 2 warrants             2,999 190
Exercise of common warrants             39,278 2,848
Share-based compensation             17,426 830
Foreign currency translation gain (loss) $ (123)     (101)     53 (62)
Net loss (8,805)     (5,059)     (37,917) (21,751)
Balance at end 97,295           97,295 47,248
As Reported                
Balance at the beginning 97,570 $ 75,941 $ 64,180 47,248 47,248 47,248 47,248  
Exercise of Series 2 warrants     1,240 1,655        
Exercise of common warrants   201 16,630 20,002        
Share-based compensation   2,597 943 435        
Foreign currency translation gain (loss)   (28) 305 (101) 204 176    
Net loss   (9,354) (7,357) (5,059) (12,416) (21,770)    
Balance at end   97,570 75,941 64,180 75,941 97,570   47,248
Common stock [Member]                
Balance at the beginning       $ 1 $ 1 $ 1 $ 1 $ 0
Balance at the beginning (In shares)       10,086,119 10,086,119 10,086,119 10,086,119 1,671,485
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs             $ 1 $ 1
Exercise of pre-funded warrants, Shares             2,374,583 953,307
Exercise of Series 2 warrants (In shares)             1,553,927 98,039
Exercise of common warrants (Shares)             10,192,840 738,187
Balance at end $ 2           $ 2 $ 1
Balance at end (In shares) 26,250,469           26,250,469 10,086,119
Common stock [Member] | As Reported                
Balance at the beginning $ 2 $ 1 $ 1 $ 1 $ 1 $ 1 $ 1  
Balance at the beginning (In shares) 25,546,288 23,451,475 17,893,765 10,086,119 10,086,119 10,086,119 10,086,119  
Exercise of pre-funded warrants, Shares     606,129 1,768,454        
Exercise of Series 2 warrants (In shares)     642,160 857,845        
Exercise of common warrants (Shares)   51,813 4,309,421 5,181,347        
Balance at end   $ 2 $ 1 $ 1 $ 1 $ 2   $ 1
Balance at end (In shares)   25,546,288 23,451,475 17,893,765 23,451,475 25,546,288   10,086,119
Additional Paid-in Capital [Member]                
Balance at the beginning       $ 238,398 $ 238,398 $ 238,398 $ 238,398 $ 168,921
Exercise of Series 2 warrants             2,999 190
Exercise of common warrants             39,278 2,848
Share-based compensation             17,426 830
Balance at end $ 326,308           326,308 238,398
Additional Paid-in Capital [Member] | As Reported                
Balance at the beginning 317,655 $ 281,498 $ 260,490 238,398 238,398 238,398 238,398  
Exercise of Series 2 warrants     1,240 1,655        
Exercise of common warrants   201 16,630 20,002        
Share-based compensation   2,597 943 435        
Restatement adjustment   5,147 2,195          
Balance at end   317,655 281,498 260,490 281,498 317,655   238,398
Accumulated Deficit [Member]                
Balance at the beginning       (190,259) (190,259) (190,259) (190,259) (167,889)
Net loss             (37,917) (21,751)
Balance at end (228,176)           (228,176) (190,259)
Accumulated Deficit [Member] | As Reported                
Balance at the beginning (219,371) (204,870) (195,318) (190,259) (190,259) (190,259) (190,259)  
Net loss   (9,354) (7,357) (5,059)        
Restatement adjustment   (5,147) (2,195)          
Balance at end   (219,371) (204,870) (195,318) (204,870) (219,371)   (190,259)
Accumulated Other Comprehensive Loss [Member]                
Balance at the beginning       (892) (892) (892) (892) (830)
Foreign currency translation gain (loss)             53 (62)
Balance at end (839)           (839) (892)
Accumulated Other Comprehensive Loss [Member] | As Reported                
Balance at the beginning $ (716) (688) (993) (892) (892) (892) (892)  
Foreign currency translation gain (loss)   (28) 305 (101)        
Balance at end   (716) $ (688) $ (993) $ (688) $ (716)   (892)
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member]                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs             $ 28,208 $ 37,072
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member] | As Reported                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs   28,213            
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member] | Common stock [Member]                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs (In Shares)             2,043,000 5,749,152
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member] | Common stock [Member] | As Reported                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs   $ 1            
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs (In Shares)   2,043,000            
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member] | Additional Paid-in Capital [Member]                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs             $ 28,207 $ 37,071
Issue Of Common Stock Prefunded Warrants And Common Stock Warrants Sold For Cash [Member] | Additional Paid-in Capital [Member] | As Reported                
Issuance of common stock and pre-funded warrants sold for cash, net of offering costs   $ 28,212